Sabine Hutchison, Co-CEO of Seuss+, argues that accountability for clinical trial outcomes cannot be delegated along with the execution work. When a biotech sponsor contracts a CRO to run a trial, operational responsibility shifts — but under ICH E6(R2) and every regulatory framework that follows from it, the sponsor remains answerable for the conduct of the study, the integrity of the data, and the protection of participants. This post is about the practical consequences of that asymmetry, and what sponsor leaders actually need to do about it.
When a sponsor contracts a CRO to manage clinical trial execution, it is reasonable to assume that responsibilities shift accordingly. Some do. Accountability does not. Under ICH E6(R2) and FDA regulations, the sponsor retains full legal and regulatory accountability for every activity delegated to an external partner, regardless of what a contract states or how comprehensively a CRO performs. This is not a compliance technicality to acknowledge once and move past. It is the governing principle that determines how authority is structured, how governance is designed, and how a sponsor responds when something goes wrong. When a sponsor treats delegation as an accountability transfer, they are not managing risk. They are creating it. The structure looks similar on the surface. The foundation beneath it is entirely different, and that difference surfaces at exactly the moment when clarity matters most.
What the Regulatory Framework Actually Says About Sponsor Accountability
ICH E6(R2) is clear on this point. Section 5.2 outlines the sponsor’s obligations when functions are transferred to a CRO, stating that the sponsor retains ultimate responsibility for the quality and integrity of trial data and for the protection of trial subjects. The regulation does not qualify this based on the volume of work delegated or the capability of the selected partner. It is categorical.
What the regulatory framework permits is the delegation of tasks. What it does not permit is the delegation of the accountability that sits behind those tasks. A sponsor can transfer the activity of monitoring to a CRO. The obligation to ensure that monitoring is conducted appropriately, and to act if it is not, remains with the sponsor.
This distinction is important to understand not as a compliance point but as a governance design principle. If accountability cannot leave the sponsor, then governance structures must be built to keep it there. That is an active and ongoing responsibility, not a passive one satisfied by the existence of a signed agreement.
The FDA’s expectations align with this framework. Sponsor oversight of contracted activities is among the most consistently cited areas in inspection findings, with inadequate oversight appearing repeatedly in warning letters across clinical development programs. Regulatory bodies expect sponsors to demonstrate genuine, substantive oversight, not documentation of delegation.
Why the Accountability Transfer Assumption Persists
The assumption forms naturally, and it forms for understandable reasons. A CRO is selected precisely because of their capability and experience. A comprehensive contract is negotiated. Scope is defined. Deliverables are specified. There is, in that moment, every reason to feel that the arrangement is well-structured and the responsibilities are clear.
What often happens next is a gradual but significant shift. As execution proceeds, the sponsor team’s attention moves toward other priorities: regulatory submissions, investor updates, board meetings, the next development milestone. The CRO’s reporting cadence becomes the primary mechanism through which the sponsor stays informed about trial execution. The governance structure, if it exists in detailed form at all, recedes into background infrastructure rather than active oversight practice.
This is not a failure of intent. It is the natural pressure pattern of a lean biotech team managing more than its bandwidth comfortably allows. What it produces, over time, is the operational reality of an accountability transfer that the regulatory framework never permitted.
What Sabine Hutchison, Co-Founder and Co-CEO at Seuss+, observes is that the shift is rarely conscious. Teams do not decide to stop overseeing their CRO. They decide to trust that everything is on track because the reporting says it is, and because raising questions would require time and operational depth they are not currently investing in maintaining.
What Fragmented Accountability Looks Like in Practice
The most revealing moment in many clinical programs is not a failure but an escalation. Something changes unexpectedly. A timeline slips. A vendor underperforms. A scope question requires a decision with downstream consequences. And in that moment, it becomes clear that no one is certain who owns the problem.
| Accountability Approach | Assumption in Practice | What Happens at the First Escalation |
|---|---|---|
| Execution and accountability treated as transferred | “The CRO owns this now” | Escalation arrives with no clear sponsor owner; resolution stalls while parties establish who decides |
| Execution delegated, accountability retained passively | “We’re responsible but they’re handling it” | Sponsor lacks operational context to make the decision; resolution is slow and poorly informed |
| Execution delegated, accountability retained actively | “We remain responsible; they execute on our behalf within our governance” | Escalation routes to sponsor promptly; decision is made with context; resolution proceeds at the right level |
Drawing on over 13 years of experience supporting biotech sponsors and work across more than 40 clinical development programs, Sabine Hutchison, Co-Founder and Co-CEO at Seuss+, has observed a consistent pattern: when governance has not been actively designed to retain accountability at the sponsor level, the first unplanned scenario exposes the gap. The escalation arrives and is met with ambiguity about who is authorized to make the decision, who has the context to make it well, and who will own the consequence.
That ambiguity is the cost of an accountability structure that was assumed rather than designed.
The Governance Architecture That Keeps Accountability With the Sponsor
Retaining accountability is not primarily a documentation exercise. It requires governance structures that function under the conditions of a real clinical program, not only under the conditions assumed when the structures were designed.
What this looks like in practice involves several connected components. Decision rights must be defined not only at the senior level but at the operational level, so that the teams closest to execution understand where authority sits and what requires escalation. Escalation paths must be established before they are needed, tested against plausible scenarios, and understood by all parties involved in the program.
The sponsor’s oversight activities must be substantive rather than performative: reviewing deliverables with enough operational engagement to detect quality signals rather than surface indicators, and maintaining enough programme awareness to ask informed questions and evaluate the answers.
The Vendor Relationship Maximization Method (VRMM), the structured five-stage system developed and applied by Seuss+ across clinical development programs, addresses this architecture directly. The first stage, Strategic Blueprint, maps sponsor accountability obligations against the vendor structure before delegation begins. The third stage, Infrastructure Setup, establishes governance with defined escalation paths, stakeholder roles, and control checkpoints that create the conditions for accountability to remain functional as a program scales.
The intention is not to add bureaucratic layer to an already complex program. It is to ensure that accountability does not drift away from the sponsor as operational complexity increases and the natural pressure to delegate and move forward intensifies.
What Changes When Accountability Is Treated as Non-Transferable
When a sponsor organization genuinely holds the principle that accountability cannot be delegated, several things change in practice.
Governance meetings become substantive rather than ceremonial, because the sponsor understands they are the party responsible if something raised in those meetings is not addressed. Escalation decisions are made with greater clarity, because the authority to act is understood to remain with the sponsor regardless of what the vendor recommends. Communication with the CRO becomes more specific and more candid, because the sponsor maintains enough operational proximity to ask informed questions.
What this requires is not a larger team or a more expensive vendor structure. It requires a deliberate decision about how the sponsor shows up in the governance relationship with its partners, and a governance architecture designed to keep that presence functional throughout the life of the program.
The sponsors who manage clinical programs most effectively under pressure are not necessarily those with the largest internal teams or the most comprehensive contracts. They are the sponsors who understand that they remain responsible even when the CRO is doing the work, and who build their governance accordingly.
It is worth acknowledging that this is harder for some organisations than others. Pre-commercial biotechs with lean teams and multiple competing priorities face genuine constraints on the bandwidth available for active oversight. That context does not change what the regulatory framework requires, but it does shape how accountability structures need to be designed: light enough to be maintained under pressure, structured enough to hold when it matters most.
Key Industry Data
- ICH E6(R2), Section 5.2: “The sponsor may transfer any or all of the sponsor’s trial-related duties and functions to a CRO, but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor.” (International Council for Harmonisation, 2016, as implemented by EMA and FDA)
- FDA BIMO Inspection Data: Inadequate sponsor oversight of contracted activities is among the most consistently cited deficiencies in FDA Bioresearch Monitoring (BIMO) clinical investigator and sponsor-monitor inspections. This finding appears recurrently in published FDA warning letters addressing clinical trial conduct across multiple therapeutic areas.
- Tufts Center for the Study of Drug Development (CSDD): Research from Tufts CSDD has documented that governance and accountability failures in sponsor-CRO relationships are among the leading organisational contributors to clinical trial delays and budget overruns, with relationship management problems accounting for a significant share of avoidable program cost increases.
- EMA Reflection Paper on Risk-Based Quality Management (EMA/INS/GCP/394194/2011): The EMA’s guidance on risk-based approaches explicitly reinforces that sponsors remain responsible for all delegated activities and must demonstrate that their oversight systems are proportionate to the complexity and risk profile of the delegated work.
- TransCelerate BioPharma Vendor Oversight Initiative: TransCelerate’s work on vendor oversight standardisation across the industry has identified accountability clarity as a foundational element of effective sponsor-CRO governance, noting that ambiguity in responsibility allocation at the contract stage creates compounding operational problems throughout trial execution.
Questions this perspective tends to raise
What does ICH E6 R2 say about sponsor accountability when a CRO is used?+
ICH E6(R2) Section 5.2 states that the sponsor may transfer any or all trial-related duties to a CRO, but the ultimate responsibility for the quality and integrity of trial data always resides with the sponsor. This means that regardless of how comprehensively a CRO is contracted, the sponsor retains full legal and regulatory accountability for every delegated activity throughout the life of the trial.
What is the difference between delegating execution and transferring accountability in clinical trials?+
Delegating execution means assigning the tasks of clinical trial management, monitoring, data collection, or oversight to an external CRO. Transferring accountability would mean the sponsor is no longer responsible for those activities. Regulatory frameworks such as ICH E6(R2) and FDA guidance do not permit the latter. The sponsor retains the obligation to ensure delegated activities are conducted appropriately and to act when they are not.
What happens to sponsor accountability when a CRO underperforms or fails to deliver?+
Sponsor accountability remains intact regardless of CRO performance. If a CRO fails to deliver, the sponsor is still responsible to regulators, ethics committees, and trial participants for the quality, safety, and integrity of the trial. This is why sponsors must maintain active governance and oversight structures that can detect underperformance early and enable timely corrective action, rather than discovering problems when options have narrowed.
How do sponsors structure accountability when working with multiple CROs simultaneously?+
Multi-CRO programs require explicit accountability mapping across each vendor relationship. This means defining decision rights at both the strategic and operational level for each vendor, establishing escalation paths that route to the sponsor rather than between vendors, and maintaining a governance structure that integrates oversight across the full vendor ecosystem rather than managing each CRO in isolation. Without this architecture, accountability becomes fragmented across vendor boundaries.
What are the signs that accountability has become blurred in a sponsor-CRO relationship?+
Key signals include: escalations that stall because no one is certain who owns the decision; governance meetings that function as status reports rather than accountability checkpoints; sponsor oversight that relies entirely on CRO-provided reporting without independent verification; and scope or budget disputes where neither party has clear authority to resolve. These patterns indicate that accountability has drifted away from the sponsor in practice, even if contractual language suggests otherwise. —
In context
This argument sits inside an industry where the cost of every clinical program is rising and the margin for recovering from a governance error is narrowing. The two numbers below are the shape of that pressure.
Accountability does not transfer with the contract. The sponsor owns the outcome whether the delegation is clean or not.
